Psych Congress Clinical Pearls to Hold Inaugural Meeting in NYC
Psych Congress Clinical Pearls will hold its inaugural meeting on November 14-15, 2026, in New York City, introducing a new regional educational series to the Psych Congress portfolio. Led by Program Chair Ilan Melnick, MD, chief medical officer, Passageway Residences of Miami-Dade County, the 2-day meeting will focus on clinical decision-making across mood disorders, schizophrenia, tardive dyskinesia, attention-deficit/hyperactivity disorder (ADHD), and neurocognitive disorders.
Case-Based Psychiatry Education for Residents and Fellows
Designed primarily for psychiatry residents and fellows, the series combines practical, case-based education with opportunities to connect with faculty and other early-career clinicians.
Presenters include academic program directors and practicing clinicians from around the country who will discuss how pharmacologic principles and emerging evidence inform diagnostic assessment and treatment selection.
Psychedelics, Depression, and Cognitive Decline in Clinical Focus
Following continued federal investment and research developments in psychedelics, Saturday’s program will open with an examination of psychedelic therapies in psychiatry. Melnick will be joined by Psych Congress Steering Committee member Brittany Albright, MD, MPH, DABOM, founder and medical director, Sweetgrass Psychiatry, and Sasidhar Gunturu, MD, DFAPA, residency training director, BronxCare Health System, to discuss patient selection, proposed mechanisms, evidence limitations, and regulatory status.
A subsequent schizophrenia session will address long-acting injectable antipsychotics, considering patient perspectives alongside dosing intervals, missed doses, access, and clinical workflow. Albright and Rebecca Roma, MD, chief medical officer, REACH, LLC, will later explore difficult-to-treat depression, including diagnostic reassessment, adherence, adequate medication trials, comorbidities, and potentially unrecognized bipolar disorder.
Cognitive decline and agitation will round out Saturday’s educational sessions as faculty discuss differentiating normal aging from mild cognitive impairment and dementia, as well as diagnostic evaluation and approaches to managing agitation.
Sunday Highlights Tardive Dyskinesia and Schizophrenia Treatment
Sunday’s opening session will address tardive dyskinesia recognition and management, including differential diagnosis, structured screening, and treatment selection. A subsequent session on muscarinic approaches to schizophrenia will cover receptor pharmacology, clinical evidence, patient selection, treatment initiation, and adverse effect management.
Gunturu, Henry Nasrallah, MD, professor and vice chair for faculty mentorship, University of Cincinnati, and Jose Rubio, MD, assistant professor, Northwell Health, will later examine bipolar disorder diagnosis and treatment. Their session will review DSM-5-TR criteria for bipolar I and bipolar II disorders and the mixed features specifier, alongside efficacy and tolerability considerations for treating acute mania, bipolar depression, and maintenance.
The meeting’s final educational session will address ADHD across the lifespan. Albright, Lee Cohen, MD, associate clinical professor of psychiatry, Columbia University Vagelos College of Physicians and Surgeons, and Manish Zinzuvadia, MD, medical director, Park Avenue Wellness Center, will review diagnostic considerations and stimulant and nonstimulant pharmacology, with a focus on selecting and titrating treatment according to age and comorbidities.
Miami Meeting Scheduled for January 2027
The Clinical Pearls series will continue January 16-17, 2027, in Miami, Florida, extending its regional approach to practical psychiatric education.
To learn more about Psych Congress Clinical Pearls, visit the meeting website.
Explore more Psych Congress events here.
